Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer|Breast Cancer Stage II-III
Interventions: DRUG: Docetaxel- Carboplatin
Sponsor: Miguel Martín Jiménez
Collaborators: UNC Lineberger Comprehensive Cancer Center|Hospital Universitario Ramon y Cajal|Hospital San Carlos, Madrid|Centro Nacional de Investigaciones Oncologicas CARLOS III